Key facts
- FEMSelect’s last known valuation is $17.0M (Sep 2022).
- It has raised $12.2M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2018.
- Notable investors include Springboard Enterprises, Keiretsu Forum, Innovation Authority, New York Angels, Robin Hood Ventures — 21 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for FEMSelect
Funding rounds
1 roundsAbout FEMSelect
Developer of medical devices designed to treat pelvic organ prolapse disease in women. The company's devices offer a minimally-invasive surgical system for suturing ligaments of the pelvic floor without overnight hospital stays and scars, enabling physicians to conduct surgery without dissection or mesh.
- Industry
- Surgical Devices
- Sector
- Healthcare
- HQ
- Newark, DE, United States
- Founded
- 2012
- Employees
- 9
- Website
- femselect.com/
- Ownership
- Privately Held (backing)
FEMSelect doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in FEMSelect shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on FEMSelect in its N-PORT filings yet. We sweep new filings monthly.